Crinetics Prescribed drugs, Inc. (CRNX) Presents at forty fourth Annual J.P. Morgan Healthcare Convention Transcript

Jessica Fye
JPMorgan Chase & Co, Analysis Division

Nice. Good morning. Welcome. My identify is Jess Fye. I am a biotech analyst at JPMorgan, and we’re persevering with the forty fourth Annual Healthcare Convention at the moment with Crinetics. You are going to hear a presentation from the administration workforce, after which we will go into some Q&A. [Operator Instructions] So with that out of the best way, I am excited to show it over to Crinetics CEO, Scott Struthers.

R. Struthers
Founder, President, CEO & Director

Thanks, Jess, and thanks all for coming. It is nice to see you. Thanks you on-line that I do know are listening and recognize seeing a few of our fellow shareholders and new shareholders and future shareholders. I have been coming at this podium right here with Jess since, what, 2018, and we began with telling you about CRN808, which was our first molecule and first-in-human knowledge. After which as 808 developed into paltusotine for the remedy of acromegaly, we up to date on that. After which we began to speak about constructing a pipeline behind it and constructing an organization behind it. And at the moment, I need to speak about constructing a enterprise behind it. Reference our forward-looking statements.

So 2025 was a breakthrough breakout yr for us. In some ways, it is a fruits of the various years of labor that we have accomplished since 2008 once we began the corporate. One of many larger achievements, in fact, was managing to get approval of a broad label for Palsonify for the remedy of acromegaly on its PDUFA date. And what I have to say